NOTE

Synthesis and Antimicrobial Study of Some New Chlorosubstituted Isoxazolines

M.R. MAURYA*, V.V. PARHATE, M.S. DESHMUKH† and P.R. RAJPUT Department of Chemistry, Vidya Bharati Mahavidyalaya, Amravati-444 602, India

Chlorosubstituted chalcones (1a-d) were allowed to react with hydroxylamine hydrochloride in DMF containing a little piperidine to give isoxazoline in 1.5 h and yields were found to be 75-80%. These compounds show antibacterial activity when assayed against some common human pathogens.

Key Words: Synthesis, AntimicrobIal activity, Chlorosubstituted isoxazolines.

It has been reported that the heterocyclic compounds containing isoxazoline ring present a broad spectrum of biological activity¹⁻³. From literature survey it has also been revealed⁴ that substituents in the phenyl ring enhance their antibacterial activity. We report here the synthesis of some hetrocyclic chlorosubstituted isoxazolines from chalcone on reaction with hydroxylamine hydrochloride in DMF containing a little piperidine. The antibactarial activity of these compounds has been tested against some gram positive (S. aureus and B. subtilis) and gram negative (E. coli and P. aeruginosa) bacteria.

A mixture of chalcone (1c) (0.01 mole and hydroxylamine hydrochloride (0.02 mole) was refluxed in DMF (25 mL) containing piperidine (0.5 mL) for 1.5 h. The reaction mixture was then poured in cold water and acidified with 1:1 HCl. The solid thus obtained was crystallised from ethanol-acetic acid mixture to get

$$C = CH = CH - Ar$$

$$O = CH - CH$$

the compound (2c). It gives colouration with ferric chloride solution and dissolves in NaOH indicating thereby the presence of free phenolic —OH group.

The spectral analysis of compound 2c is as under:

IR (nujol) show absorption band at 3200-3080 v(OH), 1630 v(C=N), 1460 $v(CH_2)$, 1160 v(C-O), 940 v(N-O), 870 v(2-furyl) and 740 cm⁻¹ v(C-Cl). UV showed λ_{max} 365 nm. Corresponding to $n \to \pi^*$ (transition) PMR (CDCl₃) showed 3.0 (dd, 1H, CH_A—CH), 3.5 (dd, 1H, CH—H_B), 5.5 (dd, 1H, CH—C), 6.7 to 7.85 (nm, 5H, Ar—H), 11.75 (S 1H, OH—).

Melting points recorded are uncorrected. The purity of the compounds was tested by TLC on microscopic slides with silica gel layers in benzene and carbon tetrachloride.

From elemental analysis, chemical properties and spectral data, the compound (2c) assigned the structure 3-(2'-hydroxy-3',5'-dichlorophenyl)-5-(2'-furyl) isoxazoline. Similarly the compounds (2a-b) were prepared by the action of hydroxylamine hydrochloride on chalcones (1a-b). The elemental analysis and physical data of compounds (2a-c) along with compound (2c) is listed in Table-1.

TABLE-1 ANALYTICAL AND PHYSICAL DATA OF ISOXAZOLINES (2a-c)

S. No.	m.f.	Yield (%)	N (%)		
			Found	Calculated	
2a	C ₁₅ H ₁₁ N ₂ O ₄ Cl ₂	78	7.82	7.90	
2 b	C ₁₅ H ₁₁ NO ₃ Cl ₂	75	4.40	4.32	
2c	C ₁₃ H ₉ NO ₃ Cl ₂	81	4.66	4.69	

The compounds (2a-c) were assayed against human pathogens gram positive S. aureus, B. subtilis and gram negative E. coli, P. aeurginosa by disc diffusion method⁵ at concentration 100 μg/mL in solvent DMF using nutrient agar medium of 14 mm depth. The disc size was 6.25 mm in diameter. The zones of inhibition were measured in mm using the following standard:

Zone of inhibition in mm: up to 8 mm, less active; 10 to 12 mm, moderate active; 12 to 14 mm, highly active.

TABLE-2 ANTIBACTERIAL ACTIVITY DATA OF COMPOUNDS (2a-c)

Compound	Substituents (Ar)	Zones of inhibition in mm				
		S. aureus	P. aeruginosa	B. subtilis	E. coli	
2a	C ₆ H ₄ NO ₂	15	14	11	14	
2b	—C ₆ H ₄ —ОН	14	15	10	16	
2c	C ₄ H ₃ O	14	14	12	15	

Most of the compounds prepared show significant antibacterial activity. The zone of inhibition was highest against S. areus, E. coli and P. aeruginosa and moderate against B. subtilis.

The bacterial species used for screening are common human pathogens. S. aureus causes supportive and invasive lesions leading to pus formation. E. coli causes secondary infection of wounds, eye and urinary tract infection, B. subtilis is responsible for urinary tract infection. The compounds (2a-c) may find application for therapeutic purposes in human diseases, provided they are non-toxic to human constitution.

ACKNOWLEDGEMENT

The authors express their sincere thanks to the Principal, Vidya Bharati Mahavidyalaya, Amravati for providing necessary laboratory facilities.

REFERENCES

- 1. G.F. Duffin and J.D. Kendall, J. Chem. Soc., 405 (1954).
- 2. Z.H. Khalil and A.S. Yanni, J. Indian Chem. Soc., 58, 168 (1981).
- 3. N.K. Mandal, R. Sinha and K.P. Bangriee, Chem. Abstr., 104, 34034v (1986).
- 4. Noll Besd, Groth Christa and Seigfried, Chem., 102 (1999).
- R. Ananthanarayan and G.K. Jagram Pancka, Text Book of Microbiology, 4th Edn., Orient Longmans (1990).
- 6. ——, Text Book of Microbiology, 4th Edn., Orient Longmans (1990).
- 7. J.P. Robert Cruickshank, B.P. Duguid, R.H.A. Swain Marmion, Medical Microbiology, 12th Edn., Vol. II, Churchill-Livingstone, Edinburgh-London-New York (1982).

(Received: 23 November 2003; Accepted: 22 January 2003) AJC-3008

THE 39th IUPAC CONGRESS

86th CONFERENCE OF THE CANADIAN SOCIETY FOR CHEMISTRY

OTTAWA, CANADA

AUGUST 10-15, 2003

Contact:

http://www.nrc.ca/confserv/iupac2003